Ultragenyx Pharmaceutical (RARE) vs. Its Competitors Critical Comparison
Ultragenyx Pharmaceutical (NASDAQ: RARE) is one of 302 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Ultragenyx Pharmaceutical to related companies based on the strength of its earnings, valuation, analyst recommendations, institutional ownership, profitability, risk and dividends.
Volatility & Risk
Ultragenyx Pharmaceutical has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical’s competitors have a beta of 6.70, suggesting that their average stock price is 570% more volatile than the S&P 500.
This table compares Ultragenyx Pharmaceutical and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Ultragenyx Pharmaceutical Competitors||-5,301.77%||-428.56%||-39.75%|
Earnings and Valuation
This table compares Ultragenyx Pharmaceutical and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Ultragenyx Pharmaceutical||$130,000.00||-$245.87 million||-7.11|
|Ultragenyx Pharmaceutical Competitors||$290.00 million||$35.57 million||1.82|
Ultragenyx Pharmaceutical’s competitors have higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
96.2% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 9.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This is a summary of current ratings and price targets for Ultragenyx Pharmaceutical and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Ultragenyx Pharmaceutical Competitors||772||3089||11294||227||2.71|
Ultragenyx Pharmaceutical currently has a consensus target price of $71.31, indicating a potential upside of 43.98%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 36.09%. Given Ultragenyx Pharmaceutical’s higher probable upside, equities research analysts clearly believe Ultragenyx Pharmaceutical is more favorable than its competitors.
Ultragenyx Pharmaceutical competitors beat Ultragenyx Pharmaceutical on 8 of the 12 factors compared.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.
Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.